Malonetta

Ethinylestradiol and Levonorgestrel, the active ingredients in Malonetta, are combined oral contraceptives presented as tablets for oral use. They work together to inhibit ovulation, thicken cervical mucus, and alter the endometrium, thereby preventing pregnancy in women of reproductive age.

GNH USA supplies Malonetta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for this EU‑market contraceptive product. The company follows validated manufacturing processes and rigorous quality control to meet EU standards.

Malonetta, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy and support menstrual cycle management.

- Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age. - Family planning: allows women to plan and space pregnancies according to personal and health considerations. - Menstrual cycle regulation: can lead to more predictable bleeding patterns while maintaining contraceptive protection.

Malonetta may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Breast tenderness - Headache - Spotting between periods

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Severe allergic reaction (anaphylaxis)

When prescribing Malonetta, consider the following precautions:

- Contraindicated in women with history of thromboembolic disorders: avoid use. - Avoid in smokers over 35 years old: increased cardiovascular risk. - Do not use during pregnancy: hormonal exposure may affect fetal development. - Monitor blood pressure regularly: combined oral contraceptives can raise BP. - Assess liver function in patients with hepatic disease: metabolism occurs in liver. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Malonetta can interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin, phenobarbital): reduce contraceptive efficacy. - Rifampin and other strong antibiotics: may lower hormone levels. - HIV protease inhibitors (e.g., ritonavir): may increase hormone concentrations leading to side effects.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase hormone levels. - St. John’s wort: may decrease effectiveness. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of bleeding.